Maze Therapeutics
South San Francisco, United States · Biotechnology, Health Care, Science And Engineering · 1,000 employees
Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations. We have assembled a world-class team that we need to rea
Funding history
- Series public offering — $144.7M — Apr 2026
- Series series d — $115.0M — Dec 2024
- Funding Round — $190.0M — Jan 2022
Recent signals
- Apr 22, 2026: Raised $144.7M in Series public offering
- Apr 21, 2026: SEC 8-K (8.01): On April 21, 2026, Maze Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC, where the Company will issue and sell a total of 5,540,000 shares of common stock at $23.50 each, along with pre-funded warrants for an additional 850,000 shares at $23.499 each. The estimated net proceeds from this offering are approximately $144.7 million after deducting underwriting discounts. This agreement allows Maze Therapeutics to raise significant capital to support its business initiatives and growth strategies.
- Sep 02, 2025: Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
- Dec 03, 2024: Raised $115.0M in Series series d
- Oct 25, 2024: Launched Maze Therapeutics Announces Positive Results for MZE829 in Phase 1 Clinical Trial for APOL1 Kidney Disease Treatment.
- Jan 10, 2022: Raised $190.0M
See plans & pricing → Track Maze Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.